Karyopharm’s Selinexor: US FDA Unconvinced By Efficacy In Single-Arm Trial

 
• By Michael McCaughan
Athletic woman training_1101761456_1200.jpg
Will a single arm be enough for Karyopharm’s proposed refractory myeloma therapy selinexor?

More from US FDA Performance Tracker

More from Regulatory Trackers